Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...

Chennai, Jan. 26 -- Highlights: ...

Aidi injection (ADI) is a traditional Chinese medicine formulation that has garnered increasing interest as an adjuvant therapy in cancer treatment. Its multi-component composition is reported to ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Blue Earth Therapeutics today announced that the first patients in the UK have been administered with the investigational ...

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug injected directly into the tumor is absorbed by macrophages, prompting them ...

— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — “This approval of fruquintinib plus sintilimab could represent a paradigm shift in managing this ...

A new cancer therapy wakes up immune cells inside tumors and turns them against cancer.

Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of ...